Skip to content

Evaluating the safety and efficacy of Unani formulation in PCOS with Secondary Amenorrhea.

Management of PCOS with Secondary Amenorrhea (Marz Akhyas Khusyathur Reham) with Herbal Unani formulation :A Randomized Control Trial of Safety and Efficacy. - nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058588
Enrollment
60
Registered
2023-10-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

Interventions

Intervention1: Polyherbal Unani formulation: Dosage Form: Decoction(Joshandha) Dose:40gms in 2 divided doses Mode of Administration: Oral Composition:1. Post-e-faloos khayar shambar(Cassia fistula Li

Sponsors

National Research Institute of Unani Medicine for Skin Disorders.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women age of 18 -40 years. Women married and unmarried. Patients have history of Absence of menstruation. Patients with USG finding of poly cystic ovaries (PCO). Patients with laboratory findings of Hyperandrogenism. Patients with associated symptoms such as Obesity ( >30), Hirsutism, Acne Vulgaris, Hyperpigmentation, etc. Patients willing to undergo lab investigations. Patients willing to participate in trial and signing in consent from.

Exclusion criteria

Exclusion criteria: Patients aged 40 year. Patients having congenital uterine abnormalities. Women with history of Hormone Replacement Therapy or using any long term medications. Pregnant or Lactating Women. Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction/auto immune diseases. Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies. Patient not willing to attend treatment schedule regularly.

Design outcomes

Primary

MeasureTime frame
Changes in USG findings.Timepoint: At baseline and 12 weeks.

Secondary

MeasureTime frame
Reduction in clinical sign and symptoms.Timepoint: At baseline, 2 weeks, 4 weeks, 8 weeks and 12 weeks.

Countries

India

Contacts

Public ContactDrByagari Saritha

National Research Institute of Unani Medicine for Skin Disorders.

aarzu763@gmail.com9032519286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026